Mid-Cavitary Obstruction in Hypertrophic Cardiomyopathy (HCM): A Rare Case Report and Management Approach.

Q3 Medicine
Acta Medica Lituanica Pub Date : 2025-01-01 Epub Date: 2025-02-18 DOI:10.15388/Amed.2025.32.1.16
Rajeev Bharadwaj, Deb Boruah, Bhupen Barman, Suman Kalita
{"title":"Mid-Cavitary Obstruction in Hypertrophic Cardiomyopathy (HCM): A Rare Case Report and Management Approach.","authors":"Rajeev Bharadwaj, Deb Boruah, Bhupen Barman, Suman Kalita","doi":"10.15388/Amed.2025.32.1.16","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertrophic cardiomyopathy (HCM) with mid-cavitary obstruction (MCO) is an uncommon condition affecting approximately 10% of HCM patients which is associated with serious outcomes, including sudden cardiac death and heart failure. We present the case of a 43-year-old male with type 2 diabetes mellitus who experienced worsening dyspnea and palpitations, leading to the diagnosis of HCM with MCO without outlet obstruction. Cardiac MRI with gadolinium contrast reveals significant mid-cavitary obstruction without left ventricular outflow tract obstruction with a scar burden of 27% and the absence of other high-risk factors such as apical aneurysm and NSVT runs on Holter monitoring. The patient was treated conservatively with the oral beta-blocker therapy, resulting in symptomatic improvement. Given the high risk of an adverse outcome, it is crucial to recognise MCO early and provide the appropriate treatment. This case report discusses the presentation, diagnosis, and management of a patient with HCM and mid-cavitary obstruction, highlighting the unique treatment considerations associated with this condition.</p><p><strong>Take home message: </strong>Mid-cavitary obstruction (MCO) in hypertrophic cardiomyopathy (HCM) is associated with high-risk outcomes of sudden cardiac death and heart failure.While beta-blockers can improve symptoms in many MCO patients, treatment should be personalized based on the symptom severity and risk factors.Patients with MCO are at risk of complications like apical aneurysms, thromboembolism, and arrhythmias.</p>","PeriodicalId":34365,"journal":{"name":"Acta Medica Lituanica","volume":"32 1","pages":"138-144"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239168/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Medica Lituanica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15388/Amed.2025.32.1.16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Hypertrophic cardiomyopathy (HCM) with mid-cavitary obstruction (MCO) is an uncommon condition affecting approximately 10% of HCM patients which is associated with serious outcomes, including sudden cardiac death and heart failure. We present the case of a 43-year-old male with type 2 diabetes mellitus who experienced worsening dyspnea and palpitations, leading to the diagnosis of HCM with MCO without outlet obstruction. Cardiac MRI with gadolinium contrast reveals significant mid-cavitary obstruction without left ventricular outflow tract obstruction with a scar burden of 27% and the absence of other high-risk factors such as apical aneurysm and NSVT runs on Holter monitoring. The patient was treated conservatively with the oral beta-blocker therapy, resulting in symptomatic improvement. Given the high risk of an adverse outcome, it is crucial to recognise MCO early and provide the appropriate treatment. This case report discusses the presentation, diagnosis, and management of a patient with HCM and mid-cavitary obstruction, highlighting the unique treatment considerations associated with this condition.

Take home message: Mid-cavitary obstruction (MCO) in hypertrophic cardiomyopathy (HCM) is associated with high-risk outcomes of sudden cardiac death and heart failure.While beta-blockers can improve symptoms in many MCO patients, treatment should be personalized based on the symptom severity and risk factors.Patients with MCO are at risk of complications like apical aneurysms, thromboembolism, and arrhythmias.

肥厚性心肌病(HCM)中腔梗阻:一例罕见病例报告及处理方法。
肥厚性心肌病(HCM)合并腔中梗阻(MCO)是一种罕见的疾病,约占10%的HCM患者,其严重后果包括心源性猝死和心力衰竭。我们报告一例43岁男性2型糖尿病患者,呼吸困难和心悸加重,导致HCM合并MCO,无出口梗阻。心脏MRI加钆造影剂显示明显腔中梗阻,无左心室流出道梗阻,瘢痕负担为27%,在动态心电图监测下无其他高危因素,如根尖动脉瘤和NSVT。患者接受口服受体阻滞剂保守治疗,症状得到改善。鉴于不良后果的高风险,早期识别MCO并提供适当的治疗至关重要。本病例报告讨论了HCM合并腔中梗阻患者的表现、诊断和治疗,强调了与这种情况相关的独特治疗注意事项。要点:肥厚性心肌病(HCM)患者的腔中梗阻(MCO)与心源性猝死和心力衰竭的高危结局相关。虽然-受体阻滞剂可以改善许多MCO患者的症状,但治疗应根据症状严重程度和危险因素进行个性化。MCO患者有发生根尖动脉瘤、血栓栓塞和心律失常等并发症的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Medica Lituanica
Acta Medica Lituanica Medicine-General Medicine
CiteScore
0.70
自引率
0.00%
发文量
33
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信